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2008;86:946--51.Ethical limits for noninvasive
ventilation prescription
Limites éticos para a prescric¸ão de ventilac¸ão
não invasiva
To  the  Editor:
Non-Invasive  Ventilation  (NIV)  is  the  treatment  of  choice  in
acute  respiratory  failure  (ARF)  related  to  Chronic  Obstruc-
tive  Pulmonary  Disease  exacerbation  and  Acute  Cardiogenic
Pulmonary  Edema.1,2 It  has  also  demonstrated  good  results
in  a  set  of  other  consensual  and  systematized  pathologies.1,2
In  addition  NIV  has  been  used  as  an  alternative  for  ARF
patients  who  have  ‘‘do-not-intubate’’  orders  either  due
to  poor  prognosis  associated  with  multiple  comorbidi-
ties  or  terminal  disease,  or  as  palliative  management  of
dyspnea.2
Aiming  to  encourage  discussion  around  this  theme,  the
authors  reviewed  508  medical  records  of  patients  undergo-
ing  NIV  between  November  2011  and  May  2013,  in  Hospital
Geral  do  Centro  Hospitalar  e  Universitário  de  Coimbra,  and
identiﬁed  15  cases  in  which  the  use  of  NIV  was  the  subject
of  ethical  considerations:  6  patients  with  advanced  cancer
disease,  5  with  multiple  organ  dysfunction,  3  with  extensive
stroke  damage,  and  one  patient  with  respiratory  failure  (RF)
Table  1  Arterial  Blood  Gas  (ABG)  parameters  evolution.
Parameters  Baseline  After  NIV  trial  P  value
pH  7.31  ±  0.18  7.36  ±  0.11  0.600
PaCO2 (mmHg)  58.3  ±  25.0  51.9  ±  12.7  0.507
PaO2/FiO2 187.9  ±  60.2  192.25  ±  67.2  0.882
NIV, non-invasive ventilation.
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ttp://dx.doi.org/10.1016/j.rppneu.2014.04.003f  central  origin.  The  patients,  4  male  and  11  females,  had
n  average  age  of  65  ±  15,  and  had  an  average  age-adjusted
harlson  comorbidity  index  of  6.5  ±  3.1.  Five  patients  pre-
ented  type  1  RF,  and  9  had  type  2  RF.  NIV  was  administered
o  one  patient  despite  a  lack  of  RF  criteria.  The  average
aO2/FiO2 ratio  was  187.9  ±  60.2,  and  average  PaCO2 was
8.3  ±  25.0  mmHg.  Seven  patients  presented  acidosis  (aver-
ge  pH:  7.19  ±  0.13):  mixed  in  4  cases,  respiratory  in  2,  and
etabolic  in  one  patient.  The  application  of  pressure  sup-
ort  ventilation  of  11.4  ±  2.8  cmH2O,  with  50.4  ±  21.7%  FiO2
ed  to  improved  pH,  PaO2/FiO2 and  PaCO2 but  showed  no
tatistical  signiﬁcance  (Table  1).  After  3.0  ±  4.2  days  of  NIV
3  of  the  15  patients  died.  None  of  the  10  patients  capa-
le  of  assessing  the  efﬁcacy  subjectively  referred  relief  of
yspnea.
In  conclusion,  we  do  not  consider  it  appropriate
o  use  NIV  in  situations  where  there  is  no  legitimate
ustiﬁcation.  On  the  contrary:  it  is  an  inefﬁcient  and  costly
pproach  and  often  leads  to  misperceptions  about  end  of
ife  management.3 With  our  limited  public  health  resources
roviding  differentiated  treatments  to  those  who  do  not
eneﬁt  from  them  could  be  considered  ethically  repre-
ensible  because,  as  a  consequence,  treatment  may  not
hen  be  available  for  those  who  would  beneﬁt.  NIV  can  on
ccasions  contribute  to  a patient’  comfort,  when  combined
ith  other  measures  (like  administration  of  morphine)  in
he  appropriate  institutions,  but  not  in  hospital  emergency
oom.
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Towards a 100% smoke-free
Portugal: No more delays
Para um Portugal 100% livre de tabaco:
Sem mais demoras
We  read  with  the  greatest  of  interest  the  study  by  Paradela
et  al.,  2013  assessing  self-reported  exposure  (e)  to  second-
hand  smoke  (SHS)  in  private/public  enclosed  settings.1
Although  only  a  regional  survey,  it  is  one  of  the  few  that
has  assessed  post-ban  perception  about  the  change  in  SHSe.
The  main  ﬁndings  are:
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•
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toll  of  death,  disability,  and  suffering  and  it  promotes
health  and  social  inequalities  and  threatens  the  coun-
try  economy  and  welfare.5 WHO  clearly  emphasises  that
only  100%  SFPs  protect  against  SHSe5 and  stresses  that
exemptions,  such  as  the  moratorium  presented  by  the  cur-
rent  Portuguese  government,  are  common  tactics  of  the
tobacco  industry  to  block  SFP  implementation.5 Moreover,
an  eminent  Portuguese  constitutionalist  has  stated  that  SFP
exemptions  are  unconstitutional:  while  failing  to  protect  all
citizens,  they  violate  the  general  principle  of  health  pro-
tection  of  Portuguese  law.2 The  Portuguese  public  health
community  should  publicly  denounce  the  interference  of
the  tobacco  industry  in  policy-making,  accordingly  to  article
5.3  of  WHO-FCTC  treaty5;  and  demand  a  100%  smoke-free
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4 Exposure  to  SHS  is  high,  signiﬁcantly  higher  in  public
leisure  settings  where  vulnerable  populations  such  as
young  people  should  be  protected  by  law.
 Young  adults  are  highly  exposed.
 Perceived  exposure  in  the  home  and  workplaces  is  similar
to  the  pre-ban  period.1
In  2013,  a  similar  survey  conducted  in  Covilhã  observed
he  same  trends.  Furthermore,  several  studies  have
eported:  (1)  high  SHSe  in  restaurants/casinos/bars/
iscos/mental  health  services;  (2)  patchy  compliance  with
he  ban,  specially  in  settings  which  allow  exemptions;  (3)
oor  ban  enforcement2 (non-published  research:  Calheiros
t  al.,  2010;  Ravara  et  al.,  2012;  Reis  et  al.,  2011).  Moreover,
ortuguese  children’s  exposure  to  SHS  is  high3;  one  of  the
ighest  in  the  EU  (non-published  research:  Reis  et  al.,  Demo-
ophes  2012),  several  studies  have  reported  low  motivation
o  quit,  few  attempts  at  giving  up,  and  an  increasing  preva-
ence  among  youth  and  females.4 These  indicators  mirror
he  failure  of  tobacco  control  policies  enacted  by  successive
overnments/legislators.  At  the  moment,  the  Portuguese
overnment  is  about  to  revise  the  smoke-free  policy  (SFP).
he  government  has  publicly  announced  its  intention  to
ass  a  100%  SFP.  However,  an  8  years  moratorium  has  been
roposed  for  hospitality  venues,  allowing  smoking  and  venti-
ation  systems,  in  order  to  ‘‘compensate  for  the  investment
ade’’.
While  governments  and  legislators  are  elected  to  pro-
ote  the  health  and  well-being  of  all  Portuguese  citizens,
hey  have  mostly  protected  tobacco  industry  and  other
‘vested  interests’’.  The  consequence  of  this  is  a  major
5ortugal  without  any  exemptions  or  delays;  as  part  of  a
omprehensive,  adequately  funded  and  enforced  tobacco
ontrol  programme.4,5 This  would  comply  with  the  Por-
uguese  government’s  obligation  following  the  WHO-FCTC
atiﬁcation  in  2005.5
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